A Phase 1 interventional study of AVT32-DRL_PB and Keytruda in Melanoma, sponsored by Alvotech Swiss AG. Recruiting at 1 site in Ukraine. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-24.
Sponsored by Alvotech Swiss AG · Phase 1, Interventional, and Treatment
How we know · 6 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Melanoma with a site in Ukraine — 4 open to participants now, 7 under way, 3 of them phase 3. Melanoma · Ukraine.
Among the 23 studies in Melanoma with a site in Ukraine, this one is the 19th largest by planned enrollment, is one of 2 that started in 2026, is one of 7 in phase 1, and was the 22nd registered.
3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.
Browse Melanoma studies →4 of the 23 studies in Melanoma with a site in Ukraine are open now. Recruiting first, the newest first:
Biocon Biologics UK PLC · Sites in Ukraine, Brazil, Chile and 7 more countries
Ages 18+
mAbxience Research S.L. · Sites in Ukraine, Bosnia and Herzegovina, Brazil and 10 more countries
Ages 18+
Vector Vitale LLC · Sites in Ukraine
Ages 18+
A study can be open while its sites in Ukraine have not opened yet or have stopped. Only those recruiting at a site in Ukraine →
Of the 467 Melanoma studies recruiting now, 379 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 5 · Phase 3 11
First in 2002; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 40 across 2,652 interventional studies indexed under Melanoma.
Median enrollment 272 across the 23 interventional studies. Of the 16 that completed or were terminated, 11 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 23 have an industry lead sponsor. The 10 most frequent:
Alvotech Swiss AG is the lead sponsor of 20 studies on the registry; 2 are open to participants now.
Alvotech Swiss AG has 1 study filed under Melanoma — fewer than ten, so there is no comparison to draw.
3 of the studies in Melanoma with a site in Ukraine that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07221734Phase 3mAbxience Research S.L.Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma | 2027-04 |
| NCT07476326Biocon Biologics UK PLCPharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma | 2027-08-16 |
| NCT07475572Alvotech Swiss AGPharmacokinetic Similarity Study to Compare AVT32-DRL_PB With Keytruda® in Participants With Fully Resected Melanoma | 2027-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 23 studies in Melanoma with a site in Ukraine, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, randomized, double-blind, parallel-group, 2 treatment group, repeated dose study to compare the PK, efficacy, safety, and immunogenicity of AVT32-DRL_PB (proposed Keytruda® biosimilar) versus Keytruda (pembrolizumab) when administered as monotherapy in participants with fully resected Stage IIB/C or Stage III melanoma requiring adjuvant treatment with pembrolizumab. Eligible participants will be randomized in a 1:1 ratio to the AVT32-DRL_PB or Keytruda treatment group and stratified by sex (female versus male) and body weight category (≤75 kg versus >75 kg). Study treatments will be administered every 3 weeks (Q3W) as an intravenous (IV) infusion over 30 minutes (1 administration Q3W is 1 treatment cycle). The administered pembrolizumab dose will be 200 mg Q3W for both treatment groups.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AVT32-DRL\_PB will be administered during double blind period and open label period
Biological: AVT32-DRL_PB
Keytruda will be administered during double blind period
Biological: Keytruda
AVT32-DRL\_PB at a dose 200 mg administered intravenously every 3 weeks.
Keytruda at a dose 200 mg administered intravenously every 3 weeks.
To demonstrate PK similarity of AVT32-DRL_PB versus Keytruda (pembrolizumab)
AUC0-3w (Cycle 1)
Time frame: Cycle 1 (each cycle is 21 days)
To demonstrate PK similarity of AVT32-DRL_PB versus Keytruda (pembrolizumab)
AUCtau,ss (Cycle 6)
Time frame: Cycle 6 (each cycle is 21 days)
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Oct 2027, 14 months after the start.
Of 226 industry-sponsored phase 1 interventional studies under Melanoma, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 66. This study's planned 14 months is below that.
Counting every sponsor, half of 412 studies reached it within 49 months; a quarter within 31 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Alvotech Swiss AG